DE60204611D1 - Sulfonyl-pyridazinon-derivate zur verwendung als aldose-reduktase-inhibitoren - Google Patents

Sulfonyl-pyridazinon-derivate zur verwendung als aldose-reduktase-inhibitoren

Info

Publication number
DE60204611D1
DE60204611D1 DE60204611T DE60204611T DE60204611D1 DE 60204611 D1 DE60204611 D1 DE 60204611D1 DE 60204611 T DE60204611 T DE 60204611T DE 60204611 T DE60204611 T DE 60204611T DE 60204611 D1 DE60204611 D1 DE 60204611D1
Authority
DE
Germany
Prior art keywords
reductase inhibitors
aldose reductase
sulfonyl
pyridazinone derivatives
prodrug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60204611T
Other languages
English (en)
Other versions
DE60204611T2 (de
Inventor
William Holt Martin
Banavara L Mylari
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Application granted granted Critical
Publication of DE60204611D1 publication Critical patent/DE60204611D1/de
Publication of DE60204611T2 publication Critical patent/DE60204611T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/18—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
DE60204611T 2001-02-28 2002-02-20 Sulfonyl-pyridazinon-derivate zur Verwendung als Aldose-reduktase-inhibitoren Expired - Fee Related DE60204611T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27225401P 2001-02-28 2001-02-28
US272254P 2001-02-28

Publications (2)

Publication Number Publication Date
DE60204611D1 true DE60204611D1 (de) 2005-07-21
DE60204611T2 DE60204611T2 (de) 2006-05-11

Family

ID=23039045

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60204611T Expired - Fee Related DE60204611T2 (de) 2001-02-28 2002-02-20 Sulfonyl-pyridazinon-derivate zur Verwendung als Aldose-reduktase-inhibitoren

Country Status (9)

Country Link
US (1) US6730674B2 (de)
EP (1) EP1236720B1 (de)
JP (1) JP2003128657A (de)
AT (1) ATE297902T1 (de)
BR (1) BR0200536A (de)
CA (1) CA2373395C (de)
DE (1) DE60204611T2 (de)
ES (1) ES2240657T3 (de)
MX (1) MXPA02002252A (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001876A (en) 1996-07-24 1999-12-14 Warner-Lambert Company Isobutylgaba and its derivatives for the treatment of pain
IL157935A0 (en) * 2001-04-30 2004-03-28 Pfizer Prod Inc Combinations of aldose reductase inhibitors and cyclooxygenase-2 inhibitors
AU761191B2 (en) 2001-05-24 2003-05-29 Pfizer Products Inc. Therapies for tissue damage resulting from ischemia
KR20030061051A (ko) * 2002-01-07 2003-07-18 대한민국 (경상대학교 총장) 신규한 아렌(혹은 알케인)술폰일피리다진온 유도체, 이의제조방법 및 유기반응에서의 용도
ATE493973T1 (de) 2004-06-04 2011-01-15 Teva Pharma Irbesartan enthaltende pharmazeutische zusammensetzung
ES2349131T3 (es) * 2005-07-21 2010-12-28 F. Hoffmann-La Roche Ag Derivados de piridazinona como agonistas del receptor de la hormona tiroidea.
SG176464A1 (en) 2008-05-09 2011-12-29 Agency Science Tech & Res Diagnosis and treatment of kawasaki disease
GB0907601D0 (en) * 2009-05-01 2009-06-10 Equateq Ltd Novel methods
WO2017168174A1 (en) 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE574204A (fr) * 1958-12-24 1959-06-24 Henri Morren Dérives de sulfonyl-pyridazine
IE47592B1 (en) 1977-12-29 1984-05-02 Ici Ltd Enzyme inhibitory phthalazin-4-ylacetic acid derivatives, pharmaceutical compositions thereof,and process for their manufacture
US4939140A (en) 1985-11-07 1990-07-03 Pfizer Inc. Heterocyclic oxophthalazinyl acetic acids
US4996204A (en) 1989-05-11 1991-02-26 Pfizer Inc. Pyrido[2,3-d]pyridazinones as aldose reductase inhibitors
FR2647676A1 (fr) 1989-06-05 1990-12-07 Union Pharma Scient Appl Nouveaux derives de pyridazinone, leurs procedes de preparation, medicaments les contenant, utiles notamment comme inhibiteurs de l'aldose reductase
AU658887B2 (en) * 1991-03-28 1995-05-04 Pfizer Inc. Pyridazinone acetic acids as aldose reductase inhibitors
TW438587B (en) 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
DE60202452C5 (de) * 2001-03-30 2006-11-23 Pfizer Products Inc., Groton Pyridazinonaldose reductase inhibitoren
AU761191B2 (en) * 2001-05-24 2003-05-29 Pfizer Products Inc. Therapies for tissue damage resulting from ischemia

Also Published As

Publication number Publication date
MXPA02002252A (es) 2002-09-30
US6730674B2 (en) 2004-05-04
ATE297902T1 (de) 2005-07-15
EP1236720B1 (de) 2005-06-15
US20030004139A1 (en) 2003-01-02
DE60204611T2 (de) 2006-05-11
CA2373395A1 (en) 2002-08-28
JP2003128657A (ja) 2003-05-08
CA2373395C (en) 2006-01-10
ES2240657T3 (es) 2005-10-16
BR0200536A (pt) 2003-04-29
EP1236720A1 (de) 2002-09-04

Similar Documents

Publication Publication Date Title
NL300927I1 (nl) tivozanib of een zout of hydraat ervan, in het bijzonder het hydrochloride-monohydraat
ATE396190T1 (de) Substituierte heteroarylalkansäure und ihre verwendung als inhibitoren der aldose reductase
ATE453393T1 (de) Verwendung von pyridylamiden als angiogenesehemmer
DE602004024988D1 (de) 2-aminopyrimidin-derivate als raf-kinase-hemmer
NO20062644L (no) DPP-IV inhibitorer
ES2182234T3 (es) Inhibidores de metaloproteasa.
IL159418A0 (en) Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
WO2004014913A3 (en) Derivatives of 2-trifluormethyl-6-aminopurine as phosphodiesterase 4 inhibitors
EP1764092A3 (de) Therapeutische strategien für die prävention und behandlung der alzeheimer-krankheit
ATE540928T1 (de) Isochinolinverbindungen und ihre medizinische verwendung
DE60234164D1 (de) Neues a-liponsäurederivat und dessen verwendung
GEP20074045B (en) (4-phenyl) piperidin-3-yl-phenylcarboxylate derivatives and related compounds as beta-secretase inhibitors for the treatment of alzheimer's disease
DE60204611D1 (de) Sulfonyl-pyridazinon-derivate zur verwendung als aldose-reduktase-inhibitoren
MXPA04006041A (es) Antivirales de piridoquinoxalina.
MX2008001778A (es) Combinacion de un agente hipnotico y un compuesto de bis arilo y heteroarilo sustituido y aplicacion terapeutica de la misma.
IL190024A0 (en) Stabilized protease composition
ATE293961T1 (de) Verwendung von hydantoin und seinen derivaten gegen hypalbuminämie
PT1072601E (pt) Derivados de 4-arilpiperidina para o tratamento de prurido
ATE334977T1 (de) Discodermolid-analoga und ihre pharmazeutische verwendung
DK1499312T3 (da) Anvendelse af hydroxypyridonderivater til sårheling
HK1066214A1 (en) Process for the preparation of 4-(imidazol-1-yl) benzenesulfonamide derivatives

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee